key: cord-0864469-sdgiaeso
authors: nan
title: Position Statement on How to Manage Patients with Diabetes and COVID-19
date: 2020-04-27
journal: J ASEAN Fed Endocr Soc
DOI: 10.15605/jafes.035.01.03
sha: 802bc87c6ed95a176dfca79e4d589e2460ae5cc9
doc_id: 864469
cord_uid: sdgiaeso

nan

Patients with diabetes and co-existing heart disease or kidney disease need special care and attempts should be made to stabilise their cardiac/renal status. 3. Attention to nutrition and adequate protein intake is important. Any deficiencies of minerals and vitamins need to be corrected. 4 . Exercise has been shown to improve immunity, though it might be prudent to be careful and avoid crowded places like gymnasia or swimming pools. 5. It is important to update influenza and pneumonia vaccinations. The latter may decrease chances of secondary bacterial pneumonia after respiratory viral infection, however, data in present viral epidemic is not available.

1. Thorough handwashing with soap and water should be encouraged since it kills the virus. Use of alcohol-based hand rubs is also useful. 2. Practice proper respiratory hygiene by covering of mouth and nose with bent elbow or tissue when coughing or sneezing. Touching of mouth, nose and eyes should be avoided. 3. Contact with an affected person needs to be minimised. Use face masks as advised if you have contact with someone with respiratory symptoms. 4. Avoid non-essential travel to major affected areas in order to restrict the spread of infection.

Patients with diabetes and COVID-19 may have more fluctuations in blood glucose levels due to conditions such as: irregular diet, reduced exercise or physical exercise, gastrointestinal symptoms; stress conditions like infection which increases glucocorticoid secretion; use of glucocorticoids in treatment can lead to a sharp rise in glucose; interruption or non-standard OAD treatment in isolation wards; fear, anxiety and tension; and COVID-19 itself can cause the human body to produce a large number of inflammatory cytokines and lead to extreme stress in some severe and critical patients.

People with diabetes are not more likely to get COVID-19 than the general population. The problem this group faces is primarily worse outcome, not a greater chance of contracting the virus. In China, where most cases have occurred so far, patients with diabetes had much higher rates of serious complications and death than those without diabetes. When sick with a viral infection, diabetes patients have an increased risk of diabetic ketoacidosis (DKA), commonly experienced by people with type 1 diabetes. Diabetic ketoacidosis can be a challenge for physician in managing fluid intake and electrolyte levels especially in sepsis and septic shock, which are serious complications found in COVID-19 patients. 11 A study by Guo et al., supported the notion that diabetes should be considered as a risk factor for a rapid progression and bad prognosis of COVID-19. They concluded that patient with diabetes should be given more attention especially in patients with rapid deterioration. 12 The UK National Health Service (NHS) has proposed a clinical guide for the management of people with diabetes during the coronavirus pandemic. 13 There are the following categories of diabetes patients to consider: 1. Obligatory admissions and inpatients: Continue to require admission and medical management, eg., diabetic ketoacidosis (DKA). We must expedite treatment to avoid delay and expedite discharge to minimise length of stay. 2. Secondary care services: Outpatient attendances should be kept to the safe minimum. Consider using virtual clinics and remote consultations. 3. Primary care delivered diabetes services: Implications for routine diabetes care should be considered in the context of broader long-term condition management and prioritisation, taking into account individual risk factors and clinical needs.

Glucose control is key in the management of diabetes with COVID-19 because it impacts Infection control. Since COVID-19 patients with diabetes have higher mortality and also a higher proportion of critically ill adults, good glycemic control during hospitalization is particularly important in the comprehensive treatment of COVID-19. In diabetes patients, each patient should have individualized blood glucose target goals and treatment strategies.

Since there are currently no specific guidelines on plasma glucose targets in patients with diabetes and COVID-19, previous existing guideline can be implemented for them. For outpatients or inpatients in general ward, plasma glucose target in fasting or pre-prandial state is 80-130 mg/dL and 1-2 hour(s) post-prandial is <180 mg/dL. Whereas patients with critical illness who are treated with continuous intravenous insulin drip in Intensive Care Units, the plasma glucose target is between 140-180 mg/dL. 14,15

Based on their experiences in China, Ma and Ran have proposed the target of blood glucose for patients with diabetes and COVID-19 based on the severity of COVID-19 (Table 1) . 16 In mild cases, both oral anti-diabetic (OAD) and insulin treatment can be maintained and it is not necessary to adjust original regimen. In moderate cases, the original treatment can be maintained if patient's mental condition, appetite and glucose control are within normal range. Patients who are previously on OAD with obvious COVID-19 symptoms that cannot eat regularly may be treated with insulin instead. Patients with premix insulin regimen may be switched to basal-bolus regimen or insulin pump to manage glucose more flexibly. In severe or critical cases, intravenous insulin should be the first-line therapy. In these cases, metformin may raise lactic acid levels, while the SGLT2 inhibitors cause volume contraction, fat metabolism, and acidosis. Glucagon-like peptide receptor-1 analogues should also be stopped since they can cause nausea and vomiting, and pioglitazone is also not recommended because it can cause fluid overload. Once the patient has recovered and stabilized even during hospitalization, the treatment can be switched back to the previous regimen and noninsulin therapy can be reintroduced. 17 Authors are required to accomplish, sign and submit scanned copies of the JAFES Author Form consisting of: (1) Authorship Certification, that authors contributed substantially to the work, that the manuscript has been read and approved by all authors, and that the requirements for authorship have been met by each author;

(2) the Author Declaration, that the article represents original material that is not being considered for publication or has not been published or accepted for publication elsewhere, that the article does not infringe or violate any copyrights or intellectual property rights, and that no references have been made to predatory/ suspected predatory journals; (3) the Author Contribution Disclosure, which lists the specific contributions of authors; and (4) the Author Publishing Agreement which retains author copyright, grants publishing and distribution rights to JAFES, and allows JAFES to apply and enforce an Attribution-Non-Commercial Creative Commons user license. Authors are also required to accomplish, sign, and submit the signed ICMJE form for Disclosure of Potential Conflicts of Interest. For original articles, authors are required to submit a scanned copy of the Ethics Review Approval of their research as well as registration in trial registries as appropriate. For manuscripts reporting data from studies involving animals, authors are required to submit a scanned copy of the Institutional Animal Care and Use Committee approval. For Case Reports or Series, and Images in Endocrinology, consent forms, are required for the publication of information about patients; otherwise, appropriate ethical clearance has been obtained from the institutional review board. Articles and any other material published in the JAFES represent the work of the author(s) and should not be construed to reflect the opinions of the Editors or the Publisher.

World Health Organization declares global emergency: A review of the

Coronavirus disease 2019 (COVID-19) Situation Report-92. Accessed 21

Novel coronavirus infection (COVID-19) in humans: A scoping review and meta-analysis

Prevalence of comorbidities and its effects in coronavirus disease 2019 patients: A systematic review and meta-analysis

Characteristics of and important lessons from the Coronavirus Disease 2019 (COVID-19) outbreak in China summary of a report of 72 314 Cases from the Chinese Center for Disease Control and Prevention

Gugus Tugas Percepatan Penanganan COVID-19. Covid19.go.id. Accessed in 21

Role of adaptive and innate immunity in type 2 diabetes mellitus

Immune dysfunction in patients with diabetes mellitus (DM)

Infections in patients with diabetes mellitus: A review of pathogenesis

Clinical considerations for patients with diabetes in times of COVID-19 epidemic

Diabetes is a risk factor for the progression and prognosis of COVID-19

Clinical guide for the management of people with diabetes during the coronavirus pandemic

The management of blood glucose should be emphasized in the treatment of COVID-19

Pedoman pengelolaan diabetes melitus Tipe 2 dewasa di Indonesia. Penerbit PB Perkeni

Diabetes care in the hospital: Standards of medical care in diabete-2020

Glucose control key with COVID-19 in diabetes